Bivalirudin in percutaneous coronary intervention

The EUROpean BiValIrudin UtiliSatION in Practice (EUROVISION) Registry

Martial Hamon, Christopher A. Nienaber, Stefano Galli, Kurt Huber, Janusz Lipiecki, Jonathan M. Hill, Nicolas Amabile, Debra Bernstein, Efthymios Deliargyris, Antoine Lafont, Philippe Gabriel Steg

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose The prospective EUROVISION Registry was designed to capture patterns of use and short term outcomes in consecutive patients undergoing PCI with bivalirudin (BIV) in European centres. Methods A total of 2018 consecutive BIV-treated patients were included from 58 sites in 5 countries (Germany, Italy, France, Austria, United Kingdom). In-hospital and 30-day outcomes were prospectively collected and included: death, myocardial infarction (MI), stroke, urgent revascularization (URV), major and minor bleeding, stent thrombosis (ST) and thrombocytopenia (TCP). Results In this all-comer population, indication for PCI included STEMI (34%), NSTEMI (25%), unstable angina (16%) and stable angina (26%). Diabetes was present in 24% of patients and 30% of cases were performed via radial access. Preloading with a P2Y12 inhibitor was frequent (74%) while procedural glycoprotein inhibitor (GPI) use was low at 4.2%. Almost half (45%) of patients had received at least one additional anticoagulant prior to receiving BIV for PCI. The overall 30-day mortality was 1.0%, with low rates of MI (1.1%), URV (0.8%), ST (0.3%) and stroke (0.2%). The rate of ACUITY major bleeding was 1.6% and no TCP was reported. Dosing variations representing possible under- or over-dosing of BIV were frequent at 35%. Conclusion In this prospective registry of consecutive patients intended for PCI, use of BIV was associated with low rates of ischemic complications and excellent safety.

Original languageEnglish
Pages (from-to)290-294
Number of pages5
JournalInternational Journal of Cardiology
Volume173
Issue number2
DOIs
Publication statusPublished - May 1 2014

Fingerprint

Percutaneous Coronary Intervention
Registries
Thrombocytopenia
Stents
Thrombosis
Stroke
Myocardial Infarction
Hemorrhage
Stable Angina
Austria
Unstable Angina
Anticoagulants
Italy
France
Germany
bivalirudin
Glycoproteins
Safety
Mortality
Population

Keywords

  • Antithrombin
  • Bivalirudin
  • PCI
  • STEMI
  • Stent thrombosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Bivalirudin in percutaneous coronary intervention : The EUROpean BiValIrudin UtiliSatION in Practice (EUROVISION) Registry. / Hamon, Martial; Nienaber, Christopher A.; Galli, Stefano; Huber, Kurt; Lipiecki, Janusz; Hill, Jonathan M.; Amabile, Nicolas; Bernstein, Debra; Deliargyris, Efthymios; Lafont, Antoine; Steg, Philippe Gabriel.

In: International Journal of Cardiology, Vol. 173, No. 2, 01.05.2014, p. 290-294.

Research output: Contribution to journalArticle

Hamon, M, Nienaber, CA, Galli, S, Huber, K, Lipiecki, J, Hill, JM, Amabile, N, Bernstein, D, Deliargyris, E, Lafont, A & Steg, PG 2014, 'Bivalirudin in percutaneous coronary intervention: The EUROpean BiValIrudin UtiliSatION in Practice (EUROVISION) Registry', International Journal of Cardiology, vol. 173, no. 2, pp. 290-294. https://doi.org/10.1016/j.ijcard.2014.03.003
Hamon, Martial ; Nienaber, Christopher A. ; Galli, Stefano ; Huber, Kurt ; Lipiecki, Janusz ; Hill, Jonathan M. ; Amabile, Nicolas ; Bernstein, Debra ; Deliargyris, Efthymios ; Lafont, Antoine ; Steg, Philippe Gabriel. / Bivalirudin in percutaneous coronary intervention : The EUROpean BiValIrudin UtiliSatION in Practice (EUROVISION) Registry. In: International Journal of Cardiology. 2014 ; Vol. 173, No. 2. pp. 290-294.
@article{29d934b920b1492b8a83a184ad5195af,
title = "Bivalirudin in percutaneous coronary intervention: The EUROpean BiValIrudin UtiliSatION in Practice (EUROVISION) Registry",
abstract = "Purpose The prospective EUROVISION Registry was designed to capture patterns of use and short term outcomes in consecutive patients undergoing PCI with bivalirudin (BIV) in European centres. Methods A total of 2018 consecutive BIV-treated patients were included from 58 sites in 5 countries (Germany, Italy, France, Austria, United Kingdom). In-hospital and 30-day outcomes were prospectively collected and included: death, myocardial infarction (MI), stroke, urgent revascularization (URV), major and minor bleeding, stent thrombosis (ST) and thrombocytopenia (TCP). Results In this all-comer population, indication for PCI included STEMI (34{\%}), NSTEMI (25{\%}), unstable angina (16{\%}) and stable angina (26{\%}). Diabetes was present in 24{\%} of patients and 30{\%} of cases were performed via radial access. Preloading with a P2Y12 inhibitor was frequent (74{\%}) while procedural glycoprotein inhibitor (GPI) use was low at 4.2{\%}. Almost half (45{\%}) of patients had received at least one additional anticoagulant prior to receiving BIV for PCI. The overall 30-day mortality was 1.0{\%}, with low rates of MI (1.1{\%}), URV (0.8{\%}), ST (0.3{\%}) and stroke (0.2{\%}). The rate of ACUITY major bleeding was 1.6{\%} and no TCP was reported. Dosing variations representing possible under- or over-dosing of BIV were frequent at 35{\%}. Conclusion In this prospective registry of consecutive patients intended for PCI, use of BIV was associated with low rates of ischemic complications and excellent safety.",
keywords = "Antithrombin, Bivalirudin, PCI, STEMI, Stent thrombosis",
author = "Martial Hamon and Nienaber, {Christopher A.} and Stefano Galli and Kurt Huber and Janusz Lipiecki and Hill, {Jonathan M.} and Nicolas Amabile and Debra Bernstein and Efthymios Deliargyris and Antoine Lafont and Steg, {Philippe Gabriel}",
year = "2014",
month = "5",
day = "1",
doi = "10.1016/j.ijcard.2014.03.003",
language = "English",
volume = "173",
pages = "290--294",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Bivalirudin in percutaneous coronary intervention

T2 - The EUROpean BiValIrudin UtiliSatION in Practice (EUROVISION) Registry

AU - Hamon, Martial

AU - Nienaber, Christopher A.

AU - Galli, Stefano

AU - Huber, Kurt

AU - Lipiecki, Janusz

AU - Hill, Jonathan M.

AU - Amabile, Nicolas

AU - Bernstein, Debra

AU - Deliargyris, Efthymios

AU - Lafont, Antoine

AU - Steg, Philippe Gabriel

PY - 2014/5/1

Y1 - 2014/5/1

N2 - Purpose The prospective EUROVISION Registry was designed to capture patterns of use and short term outcomes in consecutive patients undergoing PCI with bivalirudin (BIV) in European centres. Methods A total of 2018 consecutive BIV-treated patients were included from 58 sites in 5 countries (Germany, Italy, France, Austria, United Kingdom). In-hospital and 30-day outcomes were prospectively collected and included: death, myocardial infarction (MI), stroke, urgent revascularization (URV), major and minor bleeding, stent thrombosis (ST) and thrombocytopenia (TCP). Results In this all-comer population, indication for PCI included STEMI (34%), NSTEMI (25%), unstable angina (16%) and stable angina (26%). Diabetes was present in 24% of patients and 30% of cases were performed via radial access. Preloading with a P2Y12 inhibitor was frequent (74%) while procedural glycoprotein inhibitor (GPI) use was low at 4.2%. Almost half (45%) of patients had received at least one additional anticoagulant prior to receiving BIV for PCI. The overall 30-day mortality was 1.0%, with low rates of MI (1.1%), URV (0.8%), ST (0.3%) and stroke (0.2%). The rate of ACUITY major bleeding was 1.6% and no TCP was reported. Dosing variations representing possible under- or over-dosing of BIV were frequent at 35%. Conclusion In this prospective registry of consecutive patients intended for PCI, use of BIV was associated with low rates of ischemic complications and excellent safety.

AB - Purpose The prospective EUROVISION Registry was designed to capture patterns of use and short term outcomes in consecutive patients undergoing PCI with bivalirudin (BIV) in European centres. Methods A total of 2018 consecutive BIV-treated patients were included from 58 sites in 5 countries (Germany, Italy, France, Austria, United Kingdom). In-hospital and 30-day outcomes were prospectively collected and included: death, myocardial infarction (MI), stroke, urgent revascularization (URV), major and minor bleeding, stent thrombosis (ST) and thrombocytopenia (TCP). Results In this all-comer population, indication for PCI included STEMI (34%), NSTEMI (25%), unstable angina (16%) and stable angina (26%). Diabetes was present in 24% of patients and 30% of cases were performed via radial access. Preloading with a P2Y12 inhibitor was frequent (74%) while procedural glycoprotein inhibitor (GPI) use was low at 4.2%. Almost half (45%) of patients had received at least one additional anticoagulant prior to receiving BIV for PCI. The overall 30-day mortality was 1.0%, with low rates of MI (1.1%), URV (0.8%), ST (0.3%) and stroke (0.2%). The rate of ACUITY major bleeding was 1.6% and no TCP was reported. Dosing variations representing possible under- or over-dosing of BIV were frequent at 35%. Conclusion In this prospective registry of consecutive patients intended for PCI, use of BIV was associated with low rates of ischemic complications and excellent safety.

KW - Antithrombin

KW - Bivalirudin

KW - PCI

KW - STEMI

KW - Stent thrombosis

UR - http://www.scopus.com/inward/record.url?scp=84898904016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898904016&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2014.03.003

DO - 10.1016/j.ijcard.2014.03.003

M3 - Article

VL - 173

SP - 290

EP - 294

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 2

ER -